Effect of dobesilate on serum IL-6 and TNF-α in patients with early diabetic nephropathy

Objective To study the effect of dobesilate on serum interleukin-6（ IL-6 ）and tumor necrosis factor-α（ TNF-α）in patients with early diabetic nephropathy. Methods Eighty patients with early diabetic nephropathy were randomly divided into two groups,the observation group（ n=40 cases） and the control group（ n=40 cases）. The control group was treated with hypoglycemic,lipid-lowering, ACEI or ARB,while the observation group was treated with dobesilate based on the above therapy. They were all treated for 12 weeks. Urinary albumin excretion rate（ UAER）was measured before and after 8 and 12 weeks of treatment. Serum IL-6 and TNF-α levels were detected before and after treatment. Results There was no significant difference in UAER between the two groups before treatment（ P ﹥0. 05 ）. After 8 weeks and 12 weeks of treatment,UAER levels in the control group were significantly decreased（P﹤0. 05,P﹤0. 01）. After 4,8,12 weeks,UAER levels in the observation group were significantly lower than those before treatment（P﹤0. 05,P﹤0. 01）. Eight and 12 weeks after treatment, UAER levels in the observation group were lower than those in the control group（ P﹤0. 05 ）. After treatment,serum levels of IL-6 and TNF-α were significantly lower. Serum IL-6 level in the observation group decreased more significantly than that in the control group（ P﹤0. 05 ）. Serum TNF-α level in the observation group decreased significantly than that in the control group（ P﹤0. 01 ）. Conclusions Dobesilate can reduce the early inflammatory response in patients with diabetic nephropathy and treat disease. Key words: Diabetic nephropathy; Dobesilate; Interleukin-6 ; Tumor necrosis factor-α